PEspeaks

Jun 25, 2012
Pharmaceutical Executive
Patients who live for many years following a cancer diagnosis will likely require additional support, and a whole new kind of follow-up care.
Jun 20, 2012
Pharmaceutical Executive
Legislation fails to establish a national track-and-trace system, but tackles shortages, orphans. House and Senate leaders announced final agreement June 18, 2012 on legislation that authorizes industry user fees to support Food and Drug Administration regulatory programs.
Jun 19, 2012
Pharmaceutical Executive
Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”
Jun 17, 2012
Pharmaceutical Executive
Corporate spin-offs are on the rise across the pharmaceutical sector, but at what cost to shareholders? Brian McGilligan argues that in haste to obtain decree absolute, demerging businesses could be threatening their long-term viability.
Jun 15, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
A diverse group of HIT professionals – including physicians, academics, developers and entrepreneurs – gathered at Sudler & Hennessey’s Health and Technology Summit in New York City to discuss the challenges related to health information technology implementation, and the ways to move forward.
Jun 11, 2012
Pharmaceutical Executive
Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV.
Jun 11, 2012
Pharmaceutical Executive
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Jun 11, 2012
Pharmaceutical Executive
By admin
A new study suggests that physicians who see fewer reps are slower when it comes to dropping ‘black-box’ drugs—and at adopting promising new medications.
Jun 08, 2012
Pharmaceutical Executive
The House Appropriations Committee released the fiscal year 2013 Agriculture Appropriations bill, which, sets proposed spending levels for FDA as well as for other programs.
Jun 06, 2012
Pharmaceutical Executive
This year’s annual meeting of the American Society of Clinical Oncology (ASCO), which ended on Tuesday, provided many examples of emerging therapies that offer new hope to even those patients with metastatic disease.
native1_300x100
lorem ipsum